vs
READING INTERNATIONAL INC（RDI）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是READING INTERNATIONAL INC的1.4倍（$69.8M vs $50.3M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -5.1%，领先389.1%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -14.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 5.6%）
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
RDI vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.4倍
$50.3M
营收增速更快
RIGL
高出35.4%
-14.2%
净利率更高
RIGL
高出389.1%
-5.1%
两年增速更快
RIGL
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.3M | $69.8M |
| 净利润 | $-2.6M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | -1.9% | 33.2% |
| 净利率 | -5.1% | 384.0% |
| 营收同比 | -14.2% | 21.2% |
| 净利润同比 | -14.5% | 1769.2% |
| 每股收益（稀释后） | $-0.11 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RDIRIGL
| Q4 25 | $50.3M | $69.8M | ||
| Q3 25 | $52.2M | $69.5M | ||
| Q2 25 | $60.4M | $101.7M | ||
| Q1 25 | $40.2M | $53.3M | ||
| Q4 24 | $58.6M | $57.6M | ||
| Q3 24 | $60.1M | $55.3M | ||
| Q2 24 | $46.8M | $36.8M | ||
| Q1 24 | $45.1M | $29.5M |
净利润RDIRIGL
| Q4 25 | $-2.6M | $268.1M | ||
| Q3 25 | $-4.2M | $27.9M | ||
| Q2 25 | $-2.7M | $59.6M | ||
| Q1 25 | $-4.8M | $11.4M | ||
| Q4 24 | $-2.2M | $14.3M | ||
| Q3 24 | $-7.0M | $12.4M | ||
| Q2 24 | $-12.8M | $-1.0M | ||
| Q1 24 | $-13.2M | $-8.2M |
毛利率RDIRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率RDIRIGL
| Q4 25 | -1.9% | 33.2% | ||
| Q3 25 | -0.6% | 40.9% | ||
| Q2 25 | 4.8% | 60.1% | ||
| Q1 25 | -17.2% | 23.9% | ||
| Q4 24 | 2.6% | 28.9% | ||
| Q3 24 | -0.6% | 25.4% | ||
| Q2 24 | -16.4% | 1.2% | ||
| Q1 24 | -16.7% | -23.6% |
净利率RDIRIGL
| Q4 25 | -5.1% | 384.0% | ||
| Q3 25 | -8.0% | 40.2% | ||
| Q2 25 | -4.4% | 58.6% | ||
| Q1 25 | -11.8% | 21.5% | ||
| Q4 24 | -3.8% | 24.9% | ||
| Q3 24 | -11.7% | 22.5% | ||
| Q2 24 | -27.4% | -2.8% | ||
| Q1 24 | -29.4% | -27.9% |
每股收益（稀释后）RDIRIGL
| Q4 25 | $-0.11 | $14.11 | ||
| Q3 25 | $-0.18 | $1.46 | ||
| Q2 25 | $-0.12 | $3.28 | ||
| Q1 25 | $-0.21 | $0.63 | ||
| Q4 24 | $-0.11 | $0.82 | ||
| Q3 24 | $-0.31 | $0.70 | ||
| Q2 24 | $-0.57 | $-0.06 | ||
| Q1 24 | $-0.59 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.5M | $155.0M |
| 总债务越低越好 | $185.1M | $52.5M |
| 股东权益账面价值 | $-18.2M | $391.5M |
| 总资产 | $434.9M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资RDIRIGL
| Q4 25 | $10.5M | $155.0M | ||
| Q3 25 | $8.1M | $137.1M | ||
| Q2 25 | $9.1M | $108.4M | ||
| Q1 25 | $5.9M | $77.1M | ||
| Q4 24 | $12.4M | $77.3M | ||
| Q3 24 | $10.1M | $61.1M | ||
| Q2 24 | $9.3M | $49.1M | ||
| Q1 24 | $7.5M | $49.5M |
总债务RDIRIGL
| Q4 25 | $185.1M | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | $202.7M | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益RDIRIGL
| Q4 25 | $-18.2M | $391.5M | ||
| Q3 25 | $-12.1M | $117.6M | ||
| Q2 25 | $-7.7M | $81.9M | ||
| Q1 25 | $-8.1M | $18.6M | ||
| Q4 24 | $-4.4M | $3.3M | ||
| Q3 24 | $1.6M | $-14.6M | ||
| Q2 24 | $6.5M | $-29.9M | ||
| Q1 24 | $18.0M | $-31.7M |
总资产RDIRIGL
| Q4 25 | $434.9M | $513.6M | ||
| Q3 25 | $435.2M | $242.5M | ||
| Q2 25 | $438.1M | $206.7M | ||
| Q1 25 | $441.0M | $176.0M | ||
| Q4 24 | $471.0M | $164.0M | ||
| Q3 24 | $495.7M | $139.4M | ||
| Q2 24 | $494.9M | $128.4M | ||
| Q1 24 | $494.9M | $126.5M |
负债/权益比RDIRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $4.1M | — |
| 自由现金流率自由现金流/营收 | 8.2% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $-2.9M | — |
8季度趋势，按日历期对齐
经营现金流RDIRIGL
| Q4 25 | $4.3M | $22.0M | ||
| Q3 25 | $295.0K | $24.0M | ||
| Q2 25 | $1.6M | $30.5M | ||
| Q1 25 | $-7.7M | $-893.0K | ||
| Q4 24 | $8.0M | $14.5M | ||
| Q3 24 | $1.3M | $21.7M | ||
| Q2 24 | $-10.4M | $302.0K | ||
| Q1 24 | $-2.8M | $-5.0M |
自由现金流RDIRIGL
| Q4 25 | $4.1M | — | ||
| Q3 25 | $-246.0K | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $-8.0M | — | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-10.6M | — | ||
| Q1 24 | $-4.7M | — |
自由现金流率RDIRIGL
| Q4 25 | 8.2% | — | ||
| Q3 25 | -0.5% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | -19.8% | — | ||
| Q4 24 | 12.0% | — | ||
| Q3 24 | -1.8% | — | ||
| Q2 24 | -22.7% | — | ||
| Q1 24 | -10.4% | — |
资本支出强度RDIRIGL
| Q4 25 | 0.3% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 4.3% | — |
现金转化率RDIRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
RIGL
暂无分部数据
